Introduction: In patients with Parkinson's disease (PD), low cerebrospinal fluid (CSF) amyloid beta 1-42 (Ab42) at baseline is the most consistent CSF biomarker as a risk factor for developing dementia. Low CSF Ab42 is, however, a typical hallmark of Alzheimer's disease (AD). Hence, low CSF Ab42 in patients with PD may indicate presence of comorbid AD pathology and may predict a more AD-like cognitive profile when they develop dementia. Our study aimed to investigate if low CSF Ab42 at baseline is associated with a more AD-like cognitive profile in PD patients with dementia.
Methods: In a prospectively followed-up, population-based cohort of newly diagnosed PD patients, we compared the cognitive profile of dementia in those with a low CSF Ab42 level at baseline with that of patients who had normal levels at the time when they developed dementia. Four different cognitive domain z-scores (memory, attention, executive, visuospatial) were calculated. Patients were subdivided into three tertiles or categorized dichotomously based on the baseline CSF Ab42 levels as measured by electrochemiluminescence and ELISA.
Results: During 10-year follow-up, 37 patients met the inclusion criteria. Memory domain composite z-scores, memory subtest z-scores, and the difference between long-delay free recall versus recognition scores were not significantly different between the groups. Composite z-scores of visuospatial functions significantly differed between the tertiles, which was not significant after Bonferroni correction. In the dichotomous group analysis, z-scores of visuospatial functions significantly differed between the two groups. The other cognitive domain z-scores were not significantly different.
Conclusions: In patients with PD dementia, low CSF Ab42 level at baseline is not associated with a specific cognitive profile.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645440 | PMC |
| http://dx.doi.org/10.1159/000534552 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CSF levels of brain-derived proteins correlate with brain ventricular volume in cognitively healthy 70-year-olds.
Clin Proteomics
December 2024
Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden.
Background: The effect of varying brain ventricular volume on the cerebrospinal fluid (CSF) proteome has been discussed as possible confounding factors in comparative protein level analyses. However, the relationship between CSF volume and protein levels remains largely unexplored. Moreover, the few existing studies provide conflicting findings, indicating the need for further research.
View Article and Find Full Text PDFProjected Annual Lecanemab Treatment Eligibility in an Irish Regional Specialist Memory Clinic.
Int J Geriatr Psychiatry
October 2024
Institute of Memory and Cognition, Tallaght University Hospital, Dublin, Ireland.
Article Synopsis
- The study aims to explore patient eligibility for lecanemab therapy for Alzheimer's Disease (AD) at a Regional Specialist Memory Clinic, emphasizing the importance of timely treatment in early AD cases.
- A retrospective analysis was conducted on 188 new patients over a year, assessing their diagnostic data and biomarker status to determine eligibility based on Appropriate Use Criteria (AUC) and clinical trial standards.
- Results showed only 5.9% of the patients were eligible according to AUC, with a higher eligibility rate of 26.2% among those with biomarker positive Alzheimer's, highlighting major barriers like lack of biomarker confirmation and cognitive ineligibility.
Data-driven retrieval of population-level EEG features and their role in neurodegenerative diseases.
Brain Commun
July 2024
Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA.
Article Synopsis
- Electrophysiologic changes in neurodegenerative disorders like Alzheimer's and Lewy Body disease can be identified using EEG, providing insight into disease severity.
- Traditional EEG analysis is limited by biases from preset feature selection; this study uses a data-driven tensor decomposition method to extract key EEG activity features during resting states.
- By analyzing data from over 11,000 patients, the researchers developed an algorithm to differentiate cognitive impairment and dementia types based on identifiable EEG patterns, which showed correlations with mental status and biomarkers.
Serum Tau-A and Tau-C Levels and Their Association with Cognitive Impairment and Dementia Progression in a Memory Clinic Derived Cohort.
J Prev Alzheimers Dis
May 2024
Tobias Melton Axelsen, Sanos Clinic A/S, Herlev Hovedgade 82 1st floor, 2730 Herlev, Denmark, Email: Telephone: +4526810574.
Background: Serum-measured fragments of Tau cleaved by ADAM-10 (Tau-A) and Caspase-3 (Tau-C) have been found linked to change in cognitive function and risk of dementia.
Objectives: 1) To determine the discriminatory abilities of Tau-A, and Tau-C in subjects with either mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or AD dementia compared to a control group. 2) To determine if there is a relation between Tau-A, and Tau-C and established cerebrospinal fluid (CSF) markers of AD- β-Amyloid1-42 (AB42), Phosphorylated-tau-181 (p-tau), and total-tau.
Cognitive Profile in Parkinson's Disease Dementia Patients with Low versus Normal Cerebrospinal Fluid Amyloid Beta.
Dement Geriatr Cogn Dis Extra
October 2023
Behavioural Neurology and Movement Disorders Unit, Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Introduction: In patients with Parkinson's disease (PD), low cerebrospinal fluid (CSF) amyloid beta 1-42 (Ab42) at baseline is the most consistent CSF biomarker as a risk factor for developing dementia. Low CSF Ab42 is, however, a typical hallmark of Alzheimer's disease (AD). Hence, low CSF Ab42 in patients with PD may indicate presence of comorbid AD pathology and may predict a more AD-like cognitive profile when they develop dementia.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!